Search

Now showing items 1-7 of 7

Remdesivir for COVID‐19: evidence review of the clinical benefit and harm

Blockman, M.; Cohen, K.; De Waal, R.; Gray, A.; Kredo, T.; Maartens, G.; Nel, J.; Parrish, A.; Rees, H.; Reubenson, G. (South African National Department of Health , 2020-06-24)
Favipiravir for the prevention and management of COVID‐19: evidence review of the clinical benefit and harm

Blockman, M.; Cohen, K. ; De Waal, R.; Gray, A.; Kredo, T.; Maartens, G.; Nel, J.; Parrish, A.; Rees, H.; Reubenson, G. (South African National Department of Health, 2020-06-25)
Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harm

Parrish, A.; Gray, A. ; Kredo, T. ; Maartens, G. ; Reubenson, G.; Cohen, K.; De Waal, R.; Blockman, M.; Nel, J.; Rees, H. (South African National Department of Health, 2020-04-15)
Corticosteroids for COVID‐19: evidence review of the ckinical benefit and harm

Blockman, M.; Cohen, K.; De Waal, R.; Gray, A. ; Kredo, T.; Maartens, G.; Nel, J. ; Parrish, A.; Rees, H. ; Reubenson, G. (South African National Department of Health, 2020-07-23)
Chloroquine and hydroxychloroquine for prevention of COVID‐19: evidence review of clinical benefits and harm

Blockman, M.; Cohen, K.; De Waal, R.; Gray, A.; Kredo, T.; Maartens, G.; Nel, J.; Parrish, A.; Rees, H. (South African National Department of Health, 2020-06-18)
Lopinavir–ritonavir (LPV/r) for treatment of COVID‐19: evidence review of clinical benefits and harms

Parrish, A.; Gray, A.; Kredo, T.; Maartens, G. ; Reubenson, G.; Cohen, K. ; De Waal, R.; Blockman, M.; Nel, J.; Rees, H. (South African National Department of Health, 2020-04-22)
Azithromycin for COVID‐19: evidence review of the clinical benefit and harm

Blockman, M.; Cohen, K.; De Waal, R. ; Gray, A.; Kredo, T. ; Maartens, G. ; Nel, J.; Parrish, A.; Rees, H.; Reubenson, G. (South African National Department of Health , 2020-05-11)

Search

Filters

Remdesivir for COVID‐19: evidence review of the clinical benefit and harm

Favipiravir for the prevention and management of COVID‐19: evidence review of the clinical benefit and harm

Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harm

Corticosteroids for COVID‐19: evidence review of the ckinical benefit and harm

Chloroquine and hydroxychloroquine for prevention of COVID‐19: evidence review of clinical benefits and harm

Lopinavir–ritonavir (LPV/r) for treatment of COVID‐19: evidence review of clinical benefits and harms

Azithromycin for COVID‐19: evidence review of the clinical benefit and harm